U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Oncogene Addiction

MedGen UID:
1380646
•Concept ID:
C4505262
•
Neoplastic Process
Synonyms: Addiction, Oncogene; Addiction, Oncogenic; Oncogenic Addiction

Definition

The dependence of tumor cells on a single oncogenic pathway or protein for their continued proliferation and survival. [from MeSH]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVOncogene Addiction

Professional guidelines

PubMed

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
Novello S, Califano R, Reinmuth N, Tamma A, Puri T
Oncologist 2023 May 8;28(5):402-413. doi: 10.1093/oncolo/oyac264. PMID: 36821595Free PMC Article
New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Serrano C, Bauer S
Curr Oncol Rep 2022 Feb;24(2):151-159. Epub 2022 Jan 21 doi: 10.1007/s11912-021-01165-0. PMID: 35061196
The duality of oncomiR addiction in the maintenance and treatment of cancer.
Cheng CJ, Slack FJ
Cancer J 2012 May-Jun;18(3):232-7. doi: 10.1097/PPO.0b013e318258b75b. PMID: 22647359Free PMC Article

Recent clinical studies

Etiology

Late phase 1 studies: concepts and outcomes.
Benitez JC, Geraud A, Texier M, Massard C, Paci A, Soria JC, Besse B
Lancet Oncol 2021 Oct;22(10):e446-e455. doi: 10.1016/S1470-2045(21)00467-8. PMID: 34592194
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM, Fares AF, Le LW, Mackay KM, Soberano S, Chan SW, Smith E, Ryan M, Tsao MS, Bradbury PA, Pal P, Shepherd FA, Liu G, Leighl NB, Sacher AG
Clin Lung Cancer 2021 Jul;22(4):253-259. Epub 2021 Jan 7 doi: 10.1016/j.cllc.2020.12.015. PMID: 33582070
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
Camidge DR, Doebele RC, Kerr KM
Nat Rev Clin Oncol 2019 Jun;16(6):341-355. doi: 10.1038/s41571-019-0173-9. PMID: 30718843
From oncogene to network addiction: the new frontier of cancer genomics and therapeutics.
Tonon G
Future Oncol 2008 Aug;4(4):569-77. doi: 10.2217/14796694.4.4.569. PMID: 18684067
Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
Weinstein IB, Joe AK
Nat Clin Pract Oncol 2006 Aug;3(8):448-57. doi: 10.1038/ncponc0558. PMID: 16894390

Diagnosis

Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC).
Chen J, Zhao D, Zhang L, Zhang J, Xiao Y, Wu Q, Wang Y, Zhan Q
Cell Mol Immunol 2022 Sep;19(9):1054-1066. Epub 2022 Aug 12 doi: 10.1038/s41423-022-00903-z. PMID: 35962191Free PMC Article
Super-enhancer landscape reveals leukemia stem cell reliance on X-box binding protein 1 as a therapeutic vulnerability.
Zhou J, Wang S, Nie D, Lai P, Li Y, Li Y, Jin Y, Pan J
Sci Transl Med 2021 Sep 22;13(612):eabh3462. doi: 10.1126/scitranslmed.abh3462. PMID: 34550724
The multiple paths towards MET receptor addiction in cancer.
Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot AB, Copin MC, Tulasne D
Oncogene 2018 Jun;37(24):3200-3215. Epub 2018 Mar 19 doi: 10.1038/s41388-018-0185-4. PMID: 29551767
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.
Pagliarini R, Shao W, Sellers WR
EMBO Rep 2015 Mar;16(3):280-96. Epub 2015 Feb 13 doi: 10.15252/embr.201439949. PMID: 25680965Free PMC Article
Systematic identification of genomic markers of drug sensitivity in cancer cells.
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH
Nature 2012 Mar 28;483(7391):570-5. doi: 10.1038/nature11005. PMID: 22460902Free PMC Article

Therapy

At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.
Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L
Nat Rev Clin Oncol 2023 Mar;20(3):143-159. Epub 2023 Jan 13 doi: 10.1038/s41571-022-00718-x. PMID: 36639452
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.
Petroni G, Buqué A, Coussens LM, Galluzzi L
Nat Rev Drug Discov 2022 Jun;21(6):440-462. Epub 2022 Mar 15 doi: 10.1038/s41573-022-00415-5. PMID: 35292771
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M
Br J Cancer 2019 Oct;121(9):725-737. Epub 2019 Sep 30 doi: 10.1038/s41416-019-0573-8. PMID: 31564718Free PMC Article
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
Camidge DR, Doebele RC, Kerr KM
Nat Rev Clin Oncol 2019 Jun;16(6):341-355. doi: 10.1038/s41571-019-0173-9. PMID: 30718843
Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.
Sau S, Alsaab HO, Bhise K, Alzhrani R, Nabil G, Iyer AK
J Control Release 2018 Mar 28;274:24-34. Epub 2018 Jan 31 doi: 10.1016/j.jconrel.2018.01.028. PMID: 29391232Free PMC Article

Prognosis

At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.
Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L
Nat Rev Clin Oncol 2023 Mar;20(3):143-159. Epub 2023 Jan 13 doi: 10.1038/s41571-022-00718-x. PMID: 36639452
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM, Fares AF, Le LW, Mackay KM, Soberano S, Chan SW, Smith E, Ryan M, Tsao MS, Bradbury PA, Pal P, Shepherd FA, Liu G, Leighl NB, Sacher AG
Clin Lung Cancer 2021 Jul;22(4):253-259. Epub 2021 Jan 7 doi: 10.1016/j.cllc.2020.12.015. PMID: 33582070
Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Ziol M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, Zucman-Rossi J
J Hepatol 2021 May;74(5):1155-1166. Epub 2020 Dec 15 doi: 10.1016/j.jhep.2020.11.052. PMID: 33338512
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
Camidge DR, Doebele RC, Kerr KM
Nat Rev Clin Oncol 2019 Jun;16(6):341-355. doi: 10.1038/s41571-019-0173-9. PMID: 30718843
Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.
Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Wang T, Qi Y, Hu B, Fu H, Xie H, Zhou L, Chang Y, Zhu Y, Dai B, Zhang W, Xu J
Eur Urol 2019 May;75(5):752-763. Epub 2018 Oct 4 doi: 10.1016/j.eururo.2018.09.030. PMID: 30293904

Clinical prediction guides

At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.
Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L
Nat Rev Clin Oncol 2023 Mar;20(3):143-159. Epub 2023 Jan 13 doi: 10.1038/s41571-022-00718-x. PMID: 36639452
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM, Fares AF, Le LW, Mackay KM, Soberano S, Chan SW, Smith E, Ryan M, Tsao MS, Bradbury PA, Pal P, Shepherd FA, Liu G, Leighl NB, Sacher AG
Clin Lung Cancer 2021 Jul;22(4):253-259. Epub 2021 Jan 7 doi: 10.1016/j.cllc.2020.12.015. PMID: 33582070
The new role for an old guy: MYC as an immunoplayer.
Marinkovic D, Marinkovic T
J Cell Physiol 2021 May;236(5):3234-3243. Epub 2020 Oct 23 doi: 10.1002/jcp.30123. PMID: 33094851
Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.
Smolle E, Leithner K, Olschewski H
Thorac Cancer 2020 Feb;11(2):205-215. Epub 2019 Dec 4 doi: 10.1111/1759-7714.13246. PMID: 31799812Free PMC Article
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
Camidge DR, Doebele RC, Kerr KM
Nat Rev Clin Oncol 2019 Jun;16(6):341-355. doi: 10.1038/s41571-019-0173-9. PMID: 30718843

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...